Elix
Elix is a Tokyo-based AI drug discovery company that licenses Elix Discovery™, an all-in-one platform combining predictive models, generative AI, and physics-based simulation trained via federated learning on data from 16 pharmaceutical partners, serving enterprise pharma, biotech, and academic clients.
- Company typePrivate
- Founded2016
- HeadquartersTokyo, Japan
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Elix does
Elix, Inc. (株式会社Elix) is a Tokyo-based, privately-held AI drug discovery company founded in November 2016 by Shinya Yuki (CEO) and Tatsuya Okubo (COO). The company develops and licenses Elix Discovery™, an all-in-one AI drug discovery platform that combines predictive models (activity, ADMET, toxicity), generative AI models for molecular design (SmilesFormer, LibINVENT, SynthFormer), physics-based docking and pharmacophore simulation, and an intuitive GUI designed for medicinal chemists. Its flagship capability is a federated learning architecture — operationalized in July 2025 with the LINC consortium — that trains AI models on proprietary data from 16 pharmaceutical companies without exposing partner data, claimed as the world's first commercially available federated learning AI drug discovery platform.
Elix monetizes through enterprise platform licensing (subscription/contract) and joint research collaborations with pharmaceutical companies, biotech firms, and academic institutions. Named enterprise clients include Eisai, Kyorin Pharmaceutical, Kaken Pharmaceutical, Astellas Pharma, Shionogi, Teijin, and Tanabe (Mitsubishi Tanabe), alongside biotech partner PRISM BioLab and academic partners including Kyoto University, Tohoku University, Riken, A*STAR IMRE, and Vienna University. The company supplements its commercial offering with PhD-led consulting, open-source contributions (kMoL library, RetroSynthWAVE), and participation in industry conferences (CBI学会, BioJapan, BIO KOREA, Healthtech Summit).
The company operates with 11-50 employees from more than 10 countries, with over one-third holding PhDs in AI/ML, chemistry, biology, and physics. The founding team retains operational control, with no identified parent company. Its go-to-market is enterprise field sales targeting large Japanese pharmaceutical firms, with international expansion signaled through BIO KOREA 2026 participation and Singapore/European academic partnerships. Pricing is quote-based and not publicly disclosed.
Elix firmographics
Firmographics- Name
- Elix
- Legal name
- 株式会社Elix
- Website
- https://elix-inc.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Elix is a Tokyo-based AI drug discovery company that licenses Elix Discovery™, an all-in-one platform combining predictive models, generative AI, and physics-based simulation trained via federated learning on data from 16 pharmaceutical partners, serving enterprise pharma, biotech, and academic clients.
- Ownership category
- akta.pro rank
Elix industry classification
Industry- Product category
- AI Drug Discovery Platform
- NAICS
- Software Publishers (5132), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Cheminformatics & Molecular Modeling / CADD (HLAGAJAE)
Keywords
Where Elix is headquartered
LocationHeadquarters
- HQ city
- Tokyo
- HQ country
- Japan
- HQ region
- Asia
Offices1 record
Markets served
Elix business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations
Revenue model
- Platform Licensing (SaaS/Software): Elix Discovery™ is provided to pharmaceutical companies as a licensed software platform. Clients access predictive models, generative models, and consulting support on a subscription or contract basis. Eisai and Kyorin Pharmaceutical are named as clients with platform licenses.
- Joint Research & Collaborative Drug Discovery Projects: Elix conducts co-development research projects with pharmaceutical companies, universities, and biotech partners. These projects apply Elix's AI technologies to partner-specific drug discovery targets. Examples include collaborations with Tohoku University (targeted protein degradation), PRISM BioLab (PPI targets), and Astellas Pharma.
Go-to-market motion3 records
Distribution channels3 records
Marketing channels8 records
Elix product offering
Product offeringCore offering
Elix develops and licenses Elix Discovery™, an all-in-one AI drug discovery platform that integrates predictive models (compound activity, ADMET, toxicity), generative AI models for novel molecular structure design, GPU-accelerated physics-based simulation (docking, pharmacophore), and curated Elix Filters behind an intuitive GUI built for medicinal chemists. The platform is licensed on a subscription/contract basis to large and mid-size pharmaceutical companies and is supported by joint research projects and PhD-led consulting.
Product overview
Elix offers a portfolio centered on Elix Discovery™, an all-in-one AI drug discovery platform launched in 2022. The platform integrates predictive models for activity/ADMET prediction, generative models (SmilesFormer, SynthFormer) for molecular structure design, and expert consulting. A key differentiator is federated learning capability through kMoL, enabling AI models trained on data from 16 pharmaceutical companies without sharing proprietary data. Additional offerings include proprietary Elix Filters for drug-likeness optimization, and open-source tools (RetroSynthWAVE, Open Molecule Generator) for chemical synthesis research.
Differentiator
Problem solved
Functional benefit
Brands
- Elix Discovery™: AI drug discovery platform providing predictive models, generative models for molecular design, and consulting support for medicinal chemists
- kMoL
Products and services
- Elix Discovery™ All-in-one AI drug discovery platform providing predictive models for activity/ADMET/toxicity, generative models for molecular structure design (SmilesFormer, LibINVENT, SynthFormer), GUI-based workflow construction, Elix Filters, and PhD-led expert consulting support. Targets medicinal chemists at pharmaceutical companies with an intuitive interface for hit-to-lead optimization, structure-based and ligand-based drug design, and active learning workflows. Licensed on a subscription/contract basis to enterprise pharmaceutical clients.
- kMoL (Kyoto University – Elix open-source Library) Open-source machine and federated learning library for drug discovery, jointly developed with Kyoto University. Enables federated learning workflows that allow AI models to be trained across distributed pharmaceutical datasets while preserving data privacy. Released on GitHub under the elix-tech organization.
Quantifiable outcome
- In a joint project with PRISM BioLab, AI-driven workflow required only 1 synthesis cycle and 6 compounds to produce 2 confirmed hits with metabolic improvement, compared to 200 compounds with zero hits in a prior human-only campaign.
- +2 more outcomes
Companies that use Elix
Customer profileNamed customers7 records
Segments3 records
Ideal customer profiles3 records
Elix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability7 records
Feature7 records
Elix partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered minor and core.
- Mitsubishi CorporationminorJoint presentation at Shonan iPark Science Cafe on outcomes of the GPU Computing Resource Pilot Program for Shonan iPark tenants and future initiatives toward building an AI drug discovery ecosystem.
- Tohoku University Graduate School of Life SciencescoreJoint research agreement to develop new drug discovery methods using AI, with a focus on targeted protein degradation (TPD). The collaboration combines Elix's AI structure generation and profile prediction capabilities with Professor Minoru Ishikawa's expertise in PROTAC and protein degradation research.
- LINC (Life Intelligence Consortium)coreElix and LINC jointly commercialized the world's first AI drug discovery platform utilizing federated learning models trained on data from 16 pharmaceutical companies. The platform was developed through a project supported by the Japan Agency for Medical Research and Development (AMED). LINC is a consortium focused on life intelligence and AI-driven drug discovery.
- PRISM BioLabcoreBusiness partnership combining Elix's AI drug discovery platform with PRISM's proprietary PepMetics® peptide mimic technology for controlling protein-protein interactions (PPI). The partnership aims to accelerate drug discovery for challenging targets that have been difficult to address with conventional approaches.
- Astellas PharmacoreLongstanding joint research collaboration initiated in July 2020 focused on AI-driven drug discovery. Astellas is listed among Elix's major pharmaceutical clients and research partners.
- Kyoto University Graduate School of MedicinecoreAcademic collaboration partner. Jointly developed and released the kMoL library (October 2021), an open-source machine and federated learning library for drug discovery. Faculty members participate in joint sessions and events such as LINC SHOWCASE.
- RikenminorAcademic research partner collaborating on AI-driven drug discovery. Listed as a partner alongside other Japanese research institutions on Elix's website.
- A*STAR IMREminorSingapore-based research institute partner (Agency for Science, Technology and Research; Institute of Materials Research and Engineering). Listed as an international academic partner on Elix's website.
- Vienna UniversityminorInternational academic partner. Listed as a partner on Elix's website alongside other university collaborators.
Scale indicators5 records
Recent moves14 records
Expansion highlights6 records
Elix competitors and assessment
Company assessmentDirect peers
- Schrödinger: Schrödinger is a direct competitor offering computational chemistry and AI-driven drug discovery software (LiveDesign, Maestro) to pharmaceutical companies globally. Both companies provide physics-based and ML-driven molecular modeling platforms with predictive and generative capabilities to medicinal chemists — a directly overlapping product category and customer base.
- Insilico Medicine: Insilico Medicine operates an end-to-end AI drug discovery platform combining generative chemistry, target identification, and clinical development. Like Elix, it serves pharmaceutical partners through platform licensing and co-development, and pursues both small molecule and emerging modality discovery. Both companies compete for the same AI drug discovery customer segment.
- XtalPi: XtalPi provides AI- and physics-based drug discovery platforms combining quantum mechanics, molecular dynamics, and ML for pharmaceutical clients. It has strong commercial traction with global pharma through platform deals, paralleling Elix's enterprise sales motion. Both companies target hit identification, lead optimization, and crystal structure prediction.
- Atomwise: Atomwise operates AtomNet, an AI platform for structure-based small molecule drug discovery, and partners with pharmaceutical companies on hit identification and lead optimization. Both companies deliver AI-driven virtual screening and molecular design to pharma partners through enterprise licensing.
- Recursion Pharmaceuticals: Recursion combines high-throughput wet-lab experimentation with AI/ML models for drug discovery and has acquired Exscientia to strengthen its platform offering. It serves pharma through partnerships and internal pipeline development, overlapping with Elix's platform-plus-collaboration model.
- BenevolentAI: BenevolentAI offers an AI drug discovery platform combining knowledge graphs, ML, and biomedical data for target identification and molecule design. Both companies serve pharma through enterprise platform deals and pursue novel targets across multiple therapeutic areas.
- Exscientia: Exscientia (now part of Recursion) pioneered AI-driven end-to-end drug design using its Centaur Chemist platform. It serves pharma through co-development and platform deals, with similar use cases in hit identification and lead optimization — directly comparable to Elix's platform offering, though now operating under Recursion's umbrella.
Broad incumbents
- Isomorphic Labs: Isomorphic Labs is Alphabet's drug discovery subsidiary applying DeepMind's AI (AlphaFold) to pharmaceutical R&D. It competes for major pharma partnerships and operates with substantially more capital and compute than Elix, but targets the same enterprise AI drug discovery platform segment.
Emerging players
- Iambic Therapeutics: Iambic Therapeutics (formerly Entasis) develops AI-driven platforms for small molecule drug discovery, including novel neural network architectures for molecular property prediction. It is comparable to Elix as a platform-first AI drug discovery company but operates with an internal pipeline emphasis alongside partner programs.
- Owkin: Owkin applies federated learning and AI to biomedical research, primarily in clinical and translational settings rather than preclinical chemistry. Its federated learning infrastructure overlaps technically with Elix's kMoL approach, though Owkin focuses on patient data and clinical outcomes rather than molecular design.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Elix social profiles
Digital presenceElix financial estimates
Financial estimateRevenue estimate
Valuation estimate
Elix leadership team
Management profileNumber of profiles
Profiles5 records
Elix funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Elix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Elix
What does Elix do?
Elix develops and licenses Elix Discovery™, an all-in-one AI drug discovery platform that integrates predictive models (compound activity, ADMET, toxicity), generative AI models for novel molecular structure design, GPU-accelerated physics-based simulation (docking, pharmacophore), and curated Elix Filters behind an intuitive GUI built for medicinal chemists. The platform is licensed on a subscription/contract basis to large and mid-size pharmaceutical companies and is supported by joint research projects and PhD-led consulting.
Is Elix a public or private company?
Elix is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Elix founded?
Elix was founded in 2016. It employs 11 to 50 people.
Where is Elix based?
Elix is headquartered in Tokyo, Japan, in the Asia region.
How does Elix make money?
Two revenue lines are on record. Platform Licensing (SaaS/Software) is the primary driver. The others are joint Research & Collaborative Drug Discovery Projects.
Who are Elix's main competitors?
Direct peers on record are Schrödinger, Insilico Medicine, XtalPi, Atomwise, Recursion Pharmaceuticals, BenevolentAI and Exscientia. Isomorphic Labs is listed as a broad incumbent. Emerging players are Iambic Therapeutics and Owkin.
Does Elix have an API?
No public API is recorded for Elix.
What industry is Elix in?
Elix's product category is AI Drug Discovery Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 5132.